Immuno-Oncology | Specialty

Dr. Wakelee on BIRCH Trial for Atezolizumab in Patients With NSCLC

September 24th 2016

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, regent, International Association for the Study of Lung Cancer (IASLC) discusses updated efficacy findings from the BIRCH trial, which was a phase II study of atezolizumab (Tecentriq) for patients with PD-L1–selected advanced non–small cell lung cancer (NSCLC). Wakelee discussed these findings during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

5 Key Areas in Emerging Immunotherapy Research Stand Out

September 24th 2016

Although checkpoint blockade inhibitors targeting the PD-1/PD-L1 pathway are currently dominating the oncology community's attention, there are many other exciting approaches to anticancer immunotherapy being explored in a range of solid tumors

Published Results Affirm Efficacy of Fixed-Dose Pembrolizumab in HNSCC

September 22nd 2016

The FDA-approved fixed dose of 200 mg of pembrolizumab administered once every 3 weeks yielded durable responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Dr. David L. Rimm on Alternatives to PD-L1 to Predict Immunotherapy Response in Lung Cancer

September 22nd 2016

Pembrolizumab Approval Is Tip of the Iceberg for Immunotherapy in HNSCC

September 21st 2016

Barbara A. Burtness, MD, discussed the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.

Expert Discusses Immense Impact of Immunotherapy in GU Cancers

September 21st 2016

Elizabeth Plimack, MD, discusses some of the most impressive advancements with immunotherapy agents in the fields of renal cell carcinoma and bladder cancer, as well as remaining questions with the use of these treatments.

Dr. Antoni Ribas on the Search for Immunotherapy Biomarkers in Melanoma

September 21st 2016

Dr. Burtness on Ongoing Trials of Immunotherapy in Head and Neck Cancer

September 21st 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses some of the ongoing trials currently examining the use of immunotherapy to treat patients with head and neck cancer.

EMA Initiates Official Review of Nivolumab in Bladder Cancer

September 20th 2016

The European Medicines Agency has validated a type II variation application for use of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma who have progressed following platinum-based chemotherapy.

Dr. Kelly on the Toxicity Profile in CheckMate-227 in NSCLC

September 20th 2016

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the toxicity profile of the therapies used in the CheckMate-227 trial.

Dr. Finn on Recent Advances in the Treatment of Liver Cancer

September 20th 2016

Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses both recent advances in the treatment of patients with liver cancer, as well as the future role that immunotherapy stands to have in this field.

Rizvi Recounts Recent Immunotherapy Advances in Lung Cancer

September 20th 2016

Naiyer Rizvi, MD, discusses pivotal clinical trials of immunotherapy agents for patients with lung cancer and expresses his optimism regarding the treatment for the field.

Expert Discusses Impact of Atezolizumab in Advanced Bladder Cancer

September 15th 2016

The PD-L1 inhibitor atezolizumab has been found to be non-toxic and has demonstrated a major survival advantage in patients with metastatic urothelial bladder cancer.

Leading Researchers Dissect PD-1/PD-L1 Evidence in NSCLC

September 15th 2016

Although lung cancer remains the leading cause of cancer-related mortality in the United States and 5-year survival rates are low at 17.8%, the grim picture for this tumor type is starting to shift to a more hopeful one as its biology is becoming better understood, facilitating treatment selection and providing researchers with new therapeutic targets.

Dr. Hak Choy on Radiation and Immunotherapy in Combination in Lung Cancer

September 15th 2016

Dr. Cynthia Ma on Immunotherapy in TNBC

September 15th 2016

Dr. Wolchok on the Safety Profile in CheckMate-067 in Melanoma

September 15th 2016

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, discusses the safety profile in the CheckMate-067 trial, which examined nivolumab combined with ipilimumab in treatment-naïve patients with advanced melanoma.

Dr. El-Khoueiry on the Rationale for Evaluating Nivolumab in Advanced HCC

September 14th 2016

Anthony B. El-Khoueiry, MD, associate professor of Clinical Medicine, USC Norris Comprehensive Cancer Center, discusses the rationale for evaluating nivolumab in advanced hepatocellular carcinoma (HCC).

Dr. Ball on Eventual Role of Immunotherapy in Patients With RCC

September 14th 2016

Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the eventual role that immunotherapy will play in the treatment landscape of renal cell carcinoma (RCC), as well as patient selection to receive immunotherapy as a single agent or in combination.

Dr. Kim on Combination Therapies in Lung Cancer

September 13th 2016

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses combination therapies in the treatment of patients with lung cancer.